The Company will shortly provide a broader more detailed update presentation from its co-founder
and Executive Director Tony Charara in relation to this significant development and the Company’s
broader strategies in the immediate commercialisation of its proprietary technology as well as the
imminent commencement of Phase 3 clinical trials for its advanced wound drug candidate TR987®
....this week apparently.
Tissue Repair: Hidden Gem in Biotech!, page-132
Add TRP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
-0.010(3.64%) |
Mkt cap ! $16.02M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 27.5¢ | 26.0¢ | $34.99K | 132.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16105 | 26.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 42309 | 1 |
View Market Depth
| Last trade - 15.15pm 08/11/2024 (20 minute delay) ? |
| TRP (ASX) Chart |